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Introduction
Post-traumatic stress disorder (PTSD) is a severe psychiatric condition characterized by clinical symptoms that develop after a stressful event, such as intrusive thoughts, flashbacks, increased arousal and sleep disturbances (American Psychiatric Association, 2013) . These symptoms last for months or years and result in social and occupational disabilities (Ahmadizadeh et al., 2013) . The disease arises from the interaction among the social context, genetic susceptibility and traumatic events (Auxéméry, 2012; Yehuda et al., 2015) .
PTSD is related to a wide range of traumatic stressors. For example, sexual violence, rape and car accidents lead to PTSD in 10-20% of individuals who undergo such events (Kessler et al., 2017; Dai et al., 2018) . Individuals subjected to extreme violence, such as war veterans and refugees, are particularly susceptible to developing PTSD. It was reported that 30% of Vietnam veterans and 43% of Lebanese victims of armed conflict suffered lifetime PTSD (Kulka et al., 1990; Fares et al., 2017) . In Brazil, individuals exposed to high rates of urban violence are also more prone to developing PTSD (Ribeiro et al., 2013) .
The most commonly used medications for PTSD are selective serotonin reuptake inhibitors (SSRIs), such as paroxetine and sertraline, that relieve symptoms of depression and to some extent anxiety. The antihypertensive drug prazosin, an α1-adrenergic (α1A) receptor inverse agonist, is also used off-label to treat PTSD patients with anxiety symptoms and chronic nightmares (Khachatryan et al., 2016) . Nevertheless, the current treatment modalities only work for a minority of patients (Bailey et al., 2013; Watts et al., 2013) . Thus, there is a major need for novel therapies to provide a satisfactory solution for PTSD patients.
We have previously identified a novel anxiolytic compound, ACH-000029, that modulates the activity of both serotonergic (5-HT) and noradrenaline (NE) receptors (Azevedo et al., 2019) . This compound acts selectively at 5-HT (5-HT1A and 5-HT1D partial agonism and 5-HT2A antagonism) and α1-adrenergic (α1A, 1B and 1D antagonism) receptors, which are directly involved in the neurobiology of PTSD (Krystal and Neumeister, 2009; Bailey et al., 2013) .
Acute oral administration of ACH-000029 led to anxiolytic-like effects in mice comparable to those of clinically available drugs. Moreover, it regulated the activity of brain regions associated with the processing of emotional stimuli, such as the amygdala, retrosplenial cortex, bed nuclei of the stria terminalis and pallidum.
The current study evaluated the potential of ACH-000029 as a PTSD drug candidate by assessing its ability to reverse the anxiety-like behavior and sociability impairment induced by the single prolonged stress (SPS) protocol. SPS is a widely-used PTSD animal model that combines psychological (restraint), physiological (forced swimming), predator (bedding scent) and pharmacological (ether) stressors to produce long-term effects of severe trauma (Liberzon et al., 1997; Liberzon et al., 1999; Matar et al., 2013; Perrine et al., 2016) . We also assessed the effects of oral treatments with ACH-000029 and prazosin on modulating SPS-induced brain-wide activation to shed light on the neurocircuitry underlying PTSD. We systematically analyzed c-fos expression as a surrogate for brain activity, since c-fos is commonly used to map neural activation in stress and anxiety models due to its activity-dependent expression (Muigg et al., 2009; Mumtaz et al., 2018; Gallo et al., 2018) . Prazosin was chosen as a relevant comparator because it has been clinically tested as a PTSD treatment and acts via α1-adrenergic receptors.
Material and Methods

Drugs
ACH-000029 was synthesized as previously described (Azevedo et al., 2019) and prazosin was purchased from Sigma-Aldrich (St. Louis, MO, USA). All substances were formulated for the behavioral studies using distilled water with 0.2% hydroxypropyl methylcellulose (HPMC).
For the pharmacokinetic (PK) studies, ACH-000029 was formulated in distilled water with 0.2% HPMC and prazosin was formulated in distilled water with 5% dimethyl sulfoxide (DMSO) and 30% polyethylene glycol 400. Doses were selected based on PK data and previous studies (Azevedo et al., 2019; Stone and Zhang, 1995) .
Animals
Male C57BL/6 mice (8 to 10 week) were obtained from Cold Spring Harbor Laboratory (CSHL) or Shanghai Laboratory Animals Center and were used for the efficacy and PK studies, respectively. Animals were housed in pairs at a room temperature of 23 ± 2°C, relative humidity of 60 ± 10% and artificial lighting between 7:00 and 19:00. Food and water were available ad libitum. Behavioral testing was conducted blind to the treatment groups. Animals were maintained in accordance with the Animal Welfare act and the Department of Health and Human Services Guide for the Care and Use of Laboratory Animals. CSHL's animal facility is accredited by the American Association for Accreditation of Laboratory Animal Care. The animal procedures were approved by the CSHL's ethics committee (number 933272-15).
PK analysis
PK studies were performed in C57BL/6 mice after acute intravenous (i.v.) and oral (p.o.) dosing, n = 2 per group. The doses evaluated were: ACH-000029 at 30 mg/kg p.o., and prazosin at 1 mg/kg i.v., 3 and 10 mg/kg p.o. Plasma concentrations were analyzed over a 24hour period. For brain exposure analysis, brain and plasma samples were collected at 0.5, 1.5, 3, and 6-hour post dose, n = 3 animals per timepoint. Blood samples were collected from the jugular vein, placed in K 2 EDTA-coated tubes on wet ice, centrifuged for 5 minutes at 4°C and 6,000 rpm, transferred to cryogenic vials and stored at -80°C until analysis. Brain samples were then thawed at room temperature, diluted in water and homogenized. Compound concentrations were determined using LC-MS/MS. Brain-to-plasma ratios were calculated based on brain and plasma levels. PK parameters were estimated using the noncompartmental model in WinNonlin (V 6.3) software (Pharsight Corp, Mountainview, CA, USA).
Single prolonged stress protocol (SPS)
The SPS protocol was performed as previously described (Perrine et al., 2016; Malikowska et al., 2017) . Mice were restrained for 2 hours in a BD Falcon © 50 mL conical tube with a screwon top and air holes located 1/2 cm apart, followed by a 10-minute group swim session (n = 4-8 per swim) in a 4 L beaker (diameter = 18.4 cm), with a water depth of ∼25 cm (3.5 L) at room temperature (∼23 ºC). The animals were towel dried and returned to their original cages, where they were exposed for 15 minutes to a beaker of soiled bedding obtained from cages of sentinel rats. The mice were then gradually exposed to diethyl ether until loss of consciousness, by adding diethyl ether-soaked cotton balls at 1-minute intervals to a microisolator polycarbonate cage to minimize the rapid onset of consciousness loss. Sham animals were handled and allowed to explore an empty 4 L beaker during the duration of the protocol.
The animals were housed in new cages with fresh bedding and returned to the vivarium.
Experimental design
ACH-000029 and prazosin were assessed for their potential to modulate anxiety-like behavior and brain c-fos expression after a 7-day treatment in the SPS model. Mice (n = 10 per group) were randomized into the (i) Sham-vehicle, (ii) SPS-vehicle, (iii) SPS-ACH-000029 and (iv) SPS-prazosin groups. On day 1, they were submitted to the SPS protocol. On days 2 -8, the animals received ACH-000029 (30 mg/kg), prazosin (10 mg/kg) and vehicle p.o. twice daily.
On days 9 and 10, the mice were behaviorally assessed using the 3-chamber social interaction, open field (OFT) and elevated plus maze (EPM) tests. Then, 2.5 hours after the EPM test, the mice were anesthetized with ketamine/xylazine and euthanized by transcardial perfusion with saline and 4% formaldehyde. The brains were dissected and post fixed. Figure   1 illustrates the protocol.
Social interaction test
Sociability is the propensity to spend time with another mouse instead of exploring an empty space and is assessed as a yes-or-no (present or absent) phenotype (Yang et al., 2011) . On day 9, the mice were individually tested in a 10-minute social interaction using the 3-chamber social interaction task, in which the test animal is placed in a center chamber and given a choice to interact with a novel mouse under a small wire cup (social) or an empty cup (Nadler et al., 2004) . The animals were placed in the middle chamber for a 10-minute habituation period before the novel mouse was added to one of the side chambers and the chamber dividers were removed. The novel mice were matched in strain, age and weight to the test mice. All data were analyzed by ANY-maze software (Stoelting Co., Wood Dale, IL, USA). The behavioral parameters measured were the total traveled distance, number of entries and time spent in the area near the cup holding the interacting mouse, and number of entries and time spent in the chamber containing the stranger mouse.
OFT and EPM tests
On day 10 in the morning, the mice were tested for anxiety using the OFT, in which animals could explore a novel arena (40 x 40 x 40 cm open plexiglass box) for 5 minutes. Animal behavior was scored using ANY-maze software. The behavioral parameters were the total traveled distance, travel distance in the wall and the center area, number of center crossings and time spent in the wall and the center area. On day 10 in the afternoon, the mice were tested for 5 minutes in the EPM paradigm using the Noldus EthoVision XT apparatus (Smith et al., 2012) . Animals were considered in an arm when all four paws were simultaneously in that 
Brain-wide c-fos expression analysis
Brain activation patterns were analyzed using a brain-wide immunohistochemistry procedure that measures c-fos expression. This method consists of an automated pipeline for the analysis of neuronal activity in intact brains, by means of whole-mount immunolabeling (iDISCO+), fluorescence imaging of large cleared samples and automated cell detection and registration using the open-source software ClearMap (Osten at al., 2013; Renier et a., 2014 , Renier et al., 2016 . Samples were imaged in a sagittal orientation (right lateral side up) using light-sheet fluorescent microscopy (Ultramicroscope II, LaVision Biotec). The c-fos positive (cfos+) neurons were automatically identified by convolutional neural networks and visualized in 3D. The datasets were warped in 3D by affine and B-spline transformation to an average reference mouse brain generated from forty 8-week old C57BL/6 brains (Kim et al., 2015 and . Brain regions are organized based on the Allen Brain Atlas.
Data analysis
Behavioral data are presented as the mean + S.E.M. and were analyzed using one-way analysis of variance (ANOVA), with group as a factor, followed by the Dunnett's post hoc test.
Differences between the groups were considered significant if p<0.05. Unpaired Student's t tests were performed to determine sociability in the social interaction test, as described in Yang et al. (2011) . The c-fos data were modeled using a negative binomial distribution, commonly employed to analyze datasets with over-dispersed integer counts (Kim et al., 2016) .
Pairwise statistics were applied to identify differentially activated brain areas between the SPS-vehicle group and the other groups. The maximum likelihood coefficient β was found by iterative reweighted least squares, and then was used for estimating standard deviations and statistical significance. Z-scores were calculated based on the β coefficient normalized by its standard deviation. Brain regions were considered differentially regulated when p-values were ≤ 0.05 or z-scores were ≥ 1.65 or ≤ -1.65. To account for multiple comparison bias, p-value histograms were analyzed and left-skewed p-value distributions were adjusted at a false discovery rate of 20%, using the qvalue package in R (Storey, 2002) .
Scatter plot were built to show the relationship of the z-scores from each brain region between the SPS-vehicle versus Sham-vehicle comparison (x-axis) and the comparisons with the ACH-000029 or prazosin-treated groups (y-axis). The graph elements represent the brain regions and are illustrated with distinct shapes and colors to assist with the interpretation of the results.
Brain regions with z-factors that had an inverse relationship between the comparisons, i.e., were upregulated in the SPS-vehicle versus Sham-vehicle comparison but downregulated in the groups treated with the experimental compounds, or vice-versa, are depicted as red (up) or green (down) triangle elements. Brain regions that were only up-or downregulated in the comparison with ACH-000029 or prazosin (i.e., z-factor ≤ -1.65 or ≥ 1.65) are symbolized as red or green diamonds, respectively. Brain regions whose z-factors displayed a direct relationship between the comparisons are also shown as red (upregulated) or green (downregulated) diamonds. Brain regions that were only up-or downregulated in the SPSvehicle versus Sham-vehicle comparison are shown as purple or green oil circles, respectively.
Venn diagrams were also generated to display the common and exclusive regions regulated among the comparisons. To assess the potential of ACH-000029 or prazosin on reversing the SPS-induced activation pattern, we compared the brain regions that were up-regulated in the SPS-vehicle versus Sham with those downregulated in the comparisons using the groups treated with the test compounds (ACH-000029 or Prazosin), or vice-versa.
Results
PK analysis of the test compounds
PK studies were conducted in mice to support the dose selection of ACH-000029 and prazosin. Additional PK data previously described for ACH-000029 were also included in the analysis (Azevedo et al., 2019) . The PK behavior of the compounds suggested a twice daily oral dosing of ACH-000029 (30 mg/kg) and prazosin (10 mg/kg) ( Figure S1 and Table S1 ).
The brain-to-plasma ratio was greater for ACH-000029 (1.24-2.37) than for prazosin (0.16-0.32), as shown in Figure S2 and Table S2 . Figure 2D ) from the social chamber. The SPS-vehicle animals showed an impaired social behavior, which was observed by the lack of differences in the number of entries and time spent between the empty and social cup areas, while keeping their preference for the social arena. Interestingly, the animals subjected to the SPS protocol and treated with ACH-000029, but not with prazosin, recovered the social behavior. This finding was verified in the number of entries (t(18)=2.3, p<0.05) and in the time spent in the social cup area (t(18)=2.1, p<0.05), compared to the SPS-vehicle group. Prazosin-treated animals not only did not recover the preference for the social cup area but also lost interest for the social arena (Figures 2C and 2D) . No statistically significant differences were seen in the total traveled distance ( Figure 2E ). In the OFT, no group effect was observed (one-way ANOVA, p > 0.05; Figure 3 ).
Behavioral assessment
In the EPM test (Figure 4) , the SPS-Vehicle group showed an increased anxiety-like behavior Figure 4A ), a reduced percentage of time in the closed arms (-11.8% with p<0.01 and -10.8% with p<0.05, respectively; Figure 4C ) and a decreased anxiety index (-10% with p<0.01 and -8.5% with p<0.05, respectively; Figure 4E ), compared to the SPS-vehicle group.
The Sham-vehicle group also displayed an increased percentage of entries in the open arms (+26.5%, p<0.05; Figure 4B ) and a reduced percentage of entries in the closed arms (-10.0%, p<0.05; Figure 4D ) compared to SPS-vehicle. No statistically significant differences were observed for the SPS-prazosin compared to the SPS-vehicle group.
C-fos mapping of brain regions modulated by SPS and drug treatments
The comparative c-fos expression analysis performed at the end of the protocol identified brain regions affected by the experimental procedures. The expression of the immediate early gene c-fos is induced in neurons in response to external stimuli. Therefore, the c-fos patterns observed in this study result from the SPS-mediated exacerbation or impairment of the OFT and EPM-induced c-fos expression, or the modulation of these alterations by the test compounds. The lists of differentially activated brain areas for the SPS-vehicle versus Shamvehicle, SPS-ACH-000029 versus SPS-vehicle and SPS-Prazosin versus SPS-vehicle comparisons are shown in Tables S3, S4 and S5, respectively. The number of c-fos positive (c-fos+) cells for selected brain regions with differential activation is also plotted in Figure 5 . 
Brain regions potentially involved in the anxiolytic-like response of ACH-000029
As ACH-000029 reversed the PTSD-like phenotype in the SPS model, we hypothesized that its anxiolytic activity could be correlated with regions that were: i) changed in the SPS-vehicle versus Sham-vehicle comparison but reversed by the ACH-000029 treatment (i.e., regulated in the opposite direction in the SPS-ACH-000029 versus SPS-vehicle comparison) or ii) exclusively regulated in mice treated with ACH-000029. Figure 6B shows the relationship between the z-scores for each brain area in the SPS-vehicle versus Sham-vehicle and SPS-ACH-000029 versus SPS-vehicle comparisons. This analysis was also performed with the comparison involving the prazosin-treated group (Figure 7) . In Figure 6B , the brain areas that were regulated in the SPS-ACH-000029 versus SPS-vehicle comparison, but not in the SPS-vehicle versus Sham-vehicle comparison, are shown as red (up) or green (downregulated) diamonds. Venn diagrams were employed to visualize brain regions that were uniquely or commonly regulated between each group comparison ( Figure 8) .
Regions with z-scores that had an inverse relationship between the SPS-vehicle versus
The mice treated with ACH-000029 had a distinct c-fos activation profile compared to the animals treated with prazosin. Only ACH-000029 downregulated six brain regions (PALd, ENTm1, LSc, GPi, FF and OT2) that were upregulated in the SPS-vehicle group (Figures 6B   and 8A) . Moreover, ACH-000029 exclusively downregulated 16 brain regions: DP, DR, SSp-tr6a, SSp-tr6b, SLC, CA2sr, RSP, RSPv, RSPv, RSPv2/3, RSPv5, RSPd2/3, AOBgl, OT1, 5B and 8A) . The lateral septum areas LS and LSX were regulated by ACH-000029 and prazosin. The mice in the SPS-vehicle group also had a downregulation of the V (motor nucleus of trigeminal) and PL5 area (prelimbic cortex), which was upregulated by ACH-000029 ( Figure 8B ). ACH-000029 exclusively upregulated 13 brain regions (IF, PST, CENT2gr, XII, VISam2/3, VISam, TR3, VMHc, VMHdm, AP, Scig-c, PSV and DMX).
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Discussion
In this study, we investigated whether ACH-000029 and prazosin could reverse the PTSD-like phenotype in the SPS model. The SPS model is useful in the study of PTSD, as it produces behavioral, hormonal and molecular changes that contribute to anxiety-like behavior (Souza et al., 2017; Lisieski et al., 2018) . Moreover, it resembles key aspects of the PTSD symptomatology, such as hyperarousal and persistent avoidance of distressing memories (Borghans and Homberg, 2015) .
We reasoned that the combined modulation of specific 5-HT (5-H1A, 5-HT1D and 5-HT2A) and α1 receptors would oppose SPS-induced behavioral changes that develop after 7 days.
The 5-HT1A and 5-HT2A receptors play a role in anxiety-like behavior and retrieval of aversive memories in PTSD models (Xiang et al., 2019; Ogren et al., 2008) , and both 5-HT1A and α1 receptor variants are associated with PTSD and generalized anxiety disorder (Goçi Uka et al., 2019; Zhang et al., 2017) . The cross-talk between NE and 5-HT systems is also implicated in the residual anxiety seen in SSRI-treated patients (Blier & Briley, 2011) and in the anxiolytic effect of SSRIs (Takamura et al., 2012) . Moreover, 5-HT1A partial agonists produce synergistic anxiolytic effects when combined with SSRIs (Nishikawa et al., 2007) , suggesting that there is still room for improving the regulation of 5-HT neurotransmission in anxiety disorders, in line with the moderate efficacy of SSRIs in PTSD patients (Watts et al., 2013) .
Animals in the SPS-vehicle group exhibited an increased anxiety-related behavior in the EPM
test and a loss of social preference in the social interaction test. The 7-day treatment with ACH-000029, but not with prazosin, reversed the SPS-induced anxiety and sociability impairment phenotype. Prazosin treatment was shown to have anxiolytic actions in rodents only when used prior to stress challenges, such as alcohol deprivation (Rasmussen et al., 2017) , hyperthermia (Lecci et al., 1990) or fear conditioning (Lucas et al., 2019) . However, it does not prevent corticotrophin-releasing hormone expression (Kiss and Aguilera, 2000) , nor regulates anxiety-like behavior after stressful stimuli (Solecki et al., 2017) . Therefore, the neurobiological changes identified in PTSD and chronic stress models are dependent on other neurotransmitter systems, and blocking α1R may not be sufficient to fully inhibit stress-induced anxiety. In fact, the anxiolytic-like effect of mirtazapine requires both 5-HT1A and α1 receptors (Kakui et al., 2009) .
Mice subjected to the SPS protocol were unable to elicit sham levels of c-fos activation in several regions implicated in the stress response, including the PFC (PL5, ILA5), bed nuclei of the stria terminalis (BSTmg), amygdala and related structures (MEApd-c, PAA2, IA). Animals exposed to a single severe stressor or chronic stress present enduring decreases in novel stress-evoked c-fos expression in the hypothalamus, hippocampus, medial amygdala and prefrontal cortex (Ostrander et al., 2009; Vallès et al., 2016; Knox et al., 2016; Moench et al., 2019) . These findings suggest that persistent traumas may induce a long-lasting impairment of the corticolimbic system, perhaps as an adaptive response to chronic stress. Moreover, stressful events disrupt the control of frontal-cortical structures over limbic-striatal circuits and increase prefrontal cortex (PFC) NE and 5-HT transmission (Krystal and Neumeister, 2009) , which leads to PFC deficiency, amygdala hyperactivity and generalized hypervigilance (Fenster et al., 2018) .
ACH-000029-treated animals showed a distinct brain activation pattern compared with mice treated with prazosin. In cortical areas, only animals treated with ACH-000029 had reduced c-fos+ cells in the olfactory tubercle and retrosplenial cortex (RSC). Moreover, mice in the SPS-ACH-000029 group exhibited similar c-fos activation as the Sham-vehicle in other cortical regions, such as the anteromedial visual area (VISam), the dorsal peduncular (DP) and entorhinal areas (ENTm1). These results imply that ACH-000029 could modulate SPS-mediated changes in a cortical network involved in anxiety response (Morgan and LeDoux, 1995; de Lima et al., 2019) . This network includes the i) medial PFC, divided into dorsal (prelimbic and infralimbic cortices) and ventral (including the dorsal peduncular cortex), ii) medial visual area and iii) RSC. Interestingly, the RSC plays a role in the retrieval of emotionally valenced memories (Vann et al., 2009) , and psychological resilience during anticipation of a negative event is linked to reduced RSC activation in PTSD (Fridman et al., 2017) .
Treatment with ACH-000029 also reversed abnormal c-fos expression levels in subcortical areas altered by the SPS protocol. These areas include the globus pallidus (GPi, PALd), the lateral septum (LS) and the fields of Forel (FF). The number of c-fos+ cells in the globus pallidus was upregulated in the SPS-vehicle versus Sham-vehicle, but only downregulated in the SPS-ACH-000029 versus SPS-vehicle. Notably, the globus pallidus of PTSD patients has increased resting-state activation (Nicholson et al., 2018) and connectivity with the amygdala (Stevens et al., 2013) . In turn, the LS was initially thought to suppress anxiety by regulating the hypothalamus, although a subset of CRF receptor type 2 neurons in this region enhances stress-induced anxiety behavior (Anthony et al., 2014) . Specific cerebellum subregions (CENT2gr and LINGgr) had also increased c-fos activation in the SPS-ACH-000029 group.
The cerebellum seems to play a homeostatic role in the innate alarm system (Lanius et al., 2017) . Moreover, the cerebellum size is reduced in PTSD patients and its functional connectivity is negatively correlated with disease severity (Holmes et al., 2018) . Several brain regions were exclusively regulated by ACH-000029 treatment, such as the superior colliculus (SCig) and the ventromedial hypothalamic nucleus (VMH). The SCig area mediates anticipatory anxiety (de Almeida et al, 2006) and attenuation of fear (Baek et al., 2019) , and a disruption in the amygdala-superior colliculus connectivity is seen during subconscious processing of trauma-related words (Rabellino et al., 2016) . The VMH also participates as an integrative structure in anxiety and panic-related defensive responses (Bueno et al., 2007) . Interestingly, the anxiolytic-like effect of neuropeptide S in the SPS model is dependent on VMH activation (Jiang et al., 2018) . Finally, the dorsal raphe nucleus (DR) and its interfascicular subnucleus (IF) were also exclusively modulated by ACH-000029. It was shown that both SPS and chronic stress induce 5-HT1A expression and apoptosis in the dorsal raphe (Liu et al., 2012; Natarajan et al., 2017) , which in turn, leads to abnormal serotonergic innervation in the PFC.
In summary, our findings indicate that ACH-000029 may represent a promising pharmacotherapy for PTSD. The lower sociability and increased anxiety-like behavior induced by the SPS protocol was alleviated by a 7-day treatment with ACH-000029, but not with prazosin. The SPS protocol promoted long-lasting alterations in cortical and subcortical regions associated with stress and anxiety response, which in turn, resulted in abnormal c-fos expression levels following OFT and EPM exposure. Treatment with ACH-000029 counteracted SPS-induced alterations in the prefrontal cortex, retrosplenial cortex, globus pallidus, superior colliculus, ventromedial hypothalamus, cerebellum and dorsal raphe.
Compounds were administered during the SPS 7-day quiescent period to assess their potential to reverse the well-documented behavioral alterations after this first week (Souza et al., 2017) . However, the clinical course of the human disease is much more heterogeneous, with the disease showing early or later onset after the precipitating traumatic event, as well as rapid, slow or non-remitting symptom trajectories (Galatzer-Levy et a., 2013; Santiago et al., 2013) . Moreover, normal lifespan events, like retirement or major illness, can exacerbate existing symptoms or trigger dormant PTSD (Hiskey et al., 2008) . Therefore, preventing the progression of PTSD symptoms by early pharmacological treatment with ACH-000029 in patients with psychological distress symptoms may offer a time window to affect consolidation or reconsolidation of traumatic memories (Yehuda et al., 2015; Merlo et al., 2015) . Future studies should be conducted in PTSD animal models to further assess the efficacy of ACH-000029 and support clinical trials.
Authorship Contributions
All the authors designed the experiments, drafted and reviewed the final version of this manuscript. Experiments were performed at Certerra Inc.
Conflicts of Interest
HA, MF, AM and CRWG are employed by Ache Laboratórios Farmacêuticos. PO is a cofounder of Certerra, Inc. vehicle (y-axis). Brain regions were classified as up-or downregulated if they had a z-score of at least +1.65 or -1.65, respectively. The graph elements representing the brain regions are illustrated with different colors and shapes for visualization purposes. Brain regions with zfactors that had an inverse relationship between the comparisons, i.e., were upregulated in the SPS-vehicle versus Sham-vehicle but downregulated in the group treated with prazosin, or vice-versa, are depicted as red (up) or green (down) triangle elements. Brain regions that were up-or downregulated (i.e., z-factor ≤ -1.65 or ≥ 1.65) in the groups treated with prazosin, but not in the SPS-vehicle versus Sham-vehicle comparison are represented as red or green diamonds, respectively. Brain regions regulated in the same direction between the comparisons are also depicted as red (upregulated) or green (downregulated) diamonds. Brain regions that were only up-or downregulated in the SPS-vehicle versus Sham-vehicle comparison are shown as purple or green oil circles, respectively. Brain-wide c-fos mapping was performed 2.5 hours after the elevated plus maze test on the 10 th day of the protocol. 
